Wellcome Sanger Institute at ENA 2026

Nov 18–20, 2026 Barcelona, Spain ~1.5k attendees Website

Wellcome Sanger Institute brings 2 presentations to ENA 2026 in Barcelona. Its posters cover drug resistance and drug-induced cell states in cancer. The work tracks on-target WRN mutations emerging in MSI cancers during Werner helicase inhibitor therapy and introduces the Cancer Perturbation Atlas, which maps and reprograms drug-induced cell states in patient-derived cancer organoids.

Organization	ENA 2026 Attendance
Wellcome Sanger Institute Hinxton, UK
sanger.ac.uk Universities & institutes Genomics research institute studying cancer genomes and drug response, including CRISPR screens and patient-derived cancer models.	Poster Wed Nov 18 12–1:30pm 3:50–4:15pm 5:45–7pm Part of Poster session: Drug Resistance and Modifiers Clinical emergence of on-target WRN mutations during Werner helicase inhibitor therapy in MSI cancers Targeted agents Talk Thu Nov 19 4:35–4:40pm Part of Posters in the Spotlight, session 2 The Cancer Perturbation Atlas: mapping and reprogramming drug-induced cell states in patient-derived cancer organoids Preclinical models · Genomics

Organization

ENA 2026 Attendance

Wellcome Sanger Institute

Hinxton, UK

sanger.ac.uk

Universities & institutes

Genomics research institute studying cancer genomes and drug response, including CRISPR screens and patient-derived cancer models.

Poster

Wed Nov 18
12–1:30pm
3:50–4:15pm
5:45–7pm

Part of Poster session: Drug Resistance and Modifiers

Clinical emergence of on-target WRN mutations during Werner helicase inhibitor therapy in MSI cancers

Targeted agents